Orgenesis (ORGS) Stock Price, News & Analysis

Company Overview

Orgenesis Inc., a biotech company, focuses on cell and gene therapies worldwide. It operates through two segments, Octomera and Therapies. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed cell based POCare therapies that are processed and produced under closed and automated POCare technology systems across a collaborative POCare network consisting of research institutes and hospitals. Its therapies include autologous; cell-based immunotherapies; and therapeutics for metabolic diseases, anti-viral diseases, and tissue regeneration. The company also provides development services, including regulatory services, pre-clinical studies, intellectual property services, and GMP process translation, as well as support services; hospital services; cell process development services; and distributed cell processing services. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is headquartered in Germantown, Maryland.

Key Stats

• Today's Range: $1.90 to $2.14
• 50-Day Range: $1.77 to $3.37
• 52-Week Range: $0.87 to $10.80
• Volume: 2,563 shs
• Average Volume: 9,173 shs
• Market Capitalization: $9.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Orgenesis Stock Analysis - MarketRank™

Orgenesis scored higher than 39% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Orgenesis.

Earnings and Valuation

• Score: N/A
• Proj. Earnings Growth: N/A

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.19% of the outstanding shares of Orgenesis have been sold short.

Short Interest Ratio / Days to Cover

Orgenesis has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orgenesis has recently decreased by 30.08%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Orgenesis does not currently pay a dividend.

Dividend Growth

Orgenesis does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.49

Percentage of Shares Shorted

0.19% of the outstanding shares of Orgenesis have been sold short.

Short Interest Ratio / Days to Cover

Orgenesis has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Orgenesis has recently decreased by 30.08%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: N/A

Search Interest

Only 18 people have searched for ORGS on MarketBeat in the last 30 days. This is a decrease of -31% compared to the previous 30 days.

MarketBeat Follows

1 people have added Orgenesis to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Orgenesis insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.66% of the stock of Orgenesis is held by insiders.

Percentage Held by Institutions

Only 22.56% of the stock of Orgenesis is held by institutions.

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed this year?

Orgenesis' stock was trading at $1.89 on January 1st, 2025. Since then, ORGS shares have increased by 3.1% and is now trading at $1.9490.
View the best growth stocks for 2025 here.

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) released its quarterly earnings results on Friday, August, 11th. The company reported ($1.50) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.60 by $2.10. The business earned $6.98 million during the quarter.

When did Orgenesis' stock split?

Orgenesis's stock reverse split before market open on Wednesday, September 25th 2024. The 1-10 reverse split was announced on Monday, September 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Does Orgenesis have any subsidiaries?

The following companies are subsidiaries of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Orgenesis own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Orgenesis investors own include NVIDIA (NVDA), Energy Transfer (ET), BioLineRx (BLRX), Pfizer (PFE), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE) and Enbridge (ENB).

Company Calendar

• Last Earnings: 8/11/2023
• Today: 6/03/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ORGS
• CIK: 1460602
• Web: www.orgenesis.com
• Phone: (480) 659-6404
• Fax: N/A
• Employees: 150
• Year Founded: 2008

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$55.36 million
• Net Margins: -3,827.81%
• Pretax Margin: -3,931.93%
• Return on Equity: N/A
• Return on Assets: -130.18%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.07

Sales & Book Value

• Annual Sales: $662,000.00
• Price / Sales: 14.13
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($6.58) per share
• Price / Book: -0.30

Miscellaneous

• Outstanding Shares: 4,799,000
• Free Float: 4,527,000
• Market Cap: $9.35 million
• Optionable: No Data
• Beta: 0.72